VENLAFAXINE HYDROCHLORIDE Drug Patent Profile

Which patents cover Venlafaxine Hydrochloride, and what generic alternatives are available?

Venlafaxine Hydrochloride is a drug marketed by Alembic, Anchen Pharms, Annora Pharma, Aurobindo Pharma Ltd, Dr Reddys Labs Ltd, Granules, Inventia Hlthcare, Macleods Pharms Ltd, Medicap Labs, Nostrum Pharms Llc, Orbion Pharms, Pharmobedient, Sciegen Pharms Inc, Teva, Torrent, Valeant Pharms North, Yichang Humanwell, Zydus Pharms Usa Inc, Abon Pharms Llc, Adaptis, Ajanta Pharma Ltd, Alkem Labs Ltd, Appco, Ascent Pharms Inc, Cadila Pharms Ltd, Dexcel, Mpp Pharma, Osmotica Pharm Us, Sun Pharm, Swiss Pharm, Unique, Zydus Pharms, Alembic Pharms Ltd, Amneal Pharms, Aurobindo Pharma, Chartwell Rx, Heritage, Pliva Hrvatska Doo, Prinston Inc, Sun Pharm Inds Inc, Yaopharma Co Ltd, and Zydus Pharms Usa. and is included in forty-seven NDAs.

The generic ingredient in VENLAFAXINE HYDROCHLORIDE is venlafaxine hydrochloride. There are seventy-one drug master file entries for this compound. Sixty-five suppliers are listed for this compound. Additional details are available on the venlafaxine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Venlafaxine Hydrochloride

A generic version of VENLAFAXINE HYDROCHLORIDE was approved as venlafaxine hydrochloride by TEVA on August 3^rd, 2006.

Summary for VENLAFAXINE HYDROCHLORIDE

US Patents:	0
Applicants:	42
NDAs:	47
Finished Product Suppliers / Packagers:	63
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	215
Patent Applications:	2,435
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VENLAFAXINE HYDROCHLORIDE
What excipients (inactive ingredients) are in VENLAFAXINE HYDROCHLORIDE?	VENLAFAXINE HYDROCHLORIDE excipients list
DailyMed Link:	VENLAFAXINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for VENLAFAXINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Lakshmi N Yatham	PHASE3
Qilu Hospital of Shandong University	NA
First Affiliated Hospital of Army Medical University, PLA	NA

See all VENLAFAXINE HYDROCHLORIDE clinical trials

Pharmacology for VENLAFAXINE HYDROCHLORIDE

Drug Class	Serotonin and Norepinephrine Reuptake Inhibitor
Mechanism of Action	Norepinephrine Uptake Inhibitors Serotonin Uptake Inhibitors

Medical Subject Heading (MeSH) Categories for VENLAFAXINE HYDROCHLORIDE

Antidepressive Agents, Second-Generation

Serotonin and Noradrenaline Reuptake Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for VENLAFAXINE HYDROCHLORIDE

N06AX	Other antidepressants
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for VENLAFAXINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VENLAFAXINE HYDROCHLORIDE	Extended-release Tablets	venlafaxine hydrochloride	225 mg	022104	1	2011-01-10
VENLAFAXINE HYDROCHLORIDE	Extended-release Tablets	venlafaxine hydrochloride	37.5 mg, 75 mg and 150 mg	022104	1	2009-02-12
EFFEXOR XR	Extended-release Tablets	venlafaxine hydrochloride	37.5 mg, 75 mg and 150 mg	020699	1	2007-05-03
EFFEXOR	Tablets	venlafaxine hydrochloride	25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg	020151	1	2005-11-03

US Patents and Regulatory Information for VENLAFAXINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cadila Pharms Ltd	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	211323-001	Aug 29, 2019	AB	RX	No	No
Alembic Pharms Ltd	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET;ORAL	078932-001	Dec 14, 2010	AB	RX	No	No
Teva	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	076565-002	Jun 28, 2010	AB	RX	No	No

Expired US Patents for VENLAFAXINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Osmotica Pharm Us	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022104-004	May 20, 2008
Osmotica Pharm Us	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022104-001	May 20, 2008
Osmotica Pharm Us	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022104-004	May 20, 2008

International Patents for VENLAFAXINE HYDROCHLORIDE

See the table below for patents covering VENLAFAXINE HYDROCHLORIDE around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	9813179
Poland	318954
South Africa	9810081	Extended release formulation.

Market Dynamics and Financial Trajectory for Venlafaxine Hydrochloride

Last updated: July 27, 2025

---

Introduction

Venlafaxine hydrochloride, marketed under brand names such as Effexor, is a serotonin-norepinephrine reuptake inhibitor (SNRI) primarily used in the treatment of major depressive disorder, generalized anxiety disorder, and certain other mood disorders. Since its approval, venlafaxine has become a prominent player in the psychiatric therapeutics market, driven by evolving clinical guidelines, patent landscapes, and demographic factors. This article explores the current market dynamics and forecasts the financial trajectory of venlafaxine hydrochloride, considering key industry drivers, regulatory factors, and competitive influences.

---

Market Landscape and Key Players

Global Market Size and Growth Trends

The global antidepressant market, encompassing drugs like venlafaxine, is valued at approximately USD 19.5 billion in 2022, with projections to reach USD 28.7 billion by 2030 at a CAGR of about 4.8% (1). Venlafaxine commands a significant share within the SNRI segment, owing to its efficacy and established clinical profile.

Leading Manufacturers and Distribution Channels

Major pharmaceutical companies including Pfizer, Teva Pharmaceuticals, and ConserVal Therapeutics manufacture venlafaxine or its generic equivalents. Patent expirations in key markets have facilitated a surge in generic versions, impacting pricing and market competitiveness. Distribution channels encompass hospital pharmacies, retail drug outlets, and online pharmacies, with generic availability increasing accessibility and market penetration.

---

Market Drivers

Evolving Prescribing Practices and Clinical Guidelines

The rising prevalence of depression and anxiety disorders globally amplifies demand for effective pharmacotherapies. Clinical guidelines now favor SNRIs like venlafaxine as first- or second-line treatments, influenced by studies demonstrating comparable or superior efficacy to SSRIs, particularly in treatment-resistant cases (2). The shift promotes sustained demand.

Patent Expiry and Generics

Patent expiration is a critical determinant in market dynamics. For venlafaxine, patents expired in multiple jurisdictions between 2010 and 2015, leading to a proliferation of generic formulations. This influx has driven down prices, increased accessibility, but also compressed profit margins for branded formulations.

Regulatory Environment

Stringent approval processes, especially in the US FDA and European EMA, influence market entry and product lifecycle. Regulatory approvals of biosimilar or different formulations (e.g., extended-release variants) can alter market shares. Moreover, post-marketing safety surveillance and label updates can impact sales trajectories.

Demographic and Epidemiological Factors

The aging global population faces higher incidences of depression and comorbidities such as cardiovascular disease, increasing the pharmaceutical market’s size. In emergent markets, improved healthcare infrastructure expands diagnostic rates, further fueling demand.

---

Market Challenges

Side Effect Profile and Patient Compliance

Venlafaxine’s side effects—including nausea, increased blood pressure, and withdrawal symptoms—may influence prescriber preferences and patient adherence. The emergence of newer agents with more favorable profiles can dampen its market growth.

Pricing and Reimbursement Policies

Cost-containment measures by governments and insurers, particularly in developed markets, reduce reimbursement levels, affecting sales volume. The growth of generic options exerts downward pressure on prices.

Competition from Alternative Therapies

Innovative therapies, including norepinephrine-dopamine reuptake inhibitors (NDRIs) and novel psychotropic agents, pose competition. Additionally, non-pharmacologic interventions like psychotherapy and neuromodulation techniques are gaining traction.

---

Financial Trajectory and Forecast

Historical Revenue Trends

Revenue from venlafaxine peaked during the early 2010s, driven by high brand loyalty and limited generic competition. Post-patent expiry, revenues declined substantially, with global sales dropping from an estimated USD 1.2 billion in 2010 to approximately USD 600 million in 2018 (3).

Current Market Position

Generic variants account for over 85% of sales in mature markets, exerting a pricing ceiling on branded formulations. Revenues are expected to stabilize or decline slightly as market saturation approaches and newer therapies gain prominence.

Projected Future Growth

Despite downward pricing pressures, the global increase in mental health awareness and diagnosis sustains steady demand. Market analysts project a compound annual decline rate of approximately 1–2% for venlafaxine revenues over the next five years, primarily due to market saturation and competition.

However, strategic formulations—such as extended-release or combination products—may unlock new revenue streams. Emerging markets offer growth opportunities due to expanding healthcare access, with forecasts indicating a CAGR of about 3% in these regions.

Impact of Biosimilars and New Formulations

While biosimilars are less relevant for small-molecule drugs like venlafaxine, reformulation and combination therapies are areas of innovation that could influence the financial trajectory. For example, developing higher-dose or depot injections might capture niche markets, potentially reversing some decline trends.

---

Regulatory and Industry Influences on Financial Outlook

The regulatory landscape plays a decisive role; approval of new indications, such as in pediatric depression or off-label uses, could expand markets. Conversely, safety concerns or adverse event disclosures could hinder growth. Additionally, reimbursement policies directly influence market share, as payers favor cost-effective generics over branded versions.

---

Strategic Implications for Stakeholders

Pharmaceutical companies should focus on optimizing manufacturing efficiencies to offset declining revenues from original formulations. Investing in niche indications and exploring combination therapies can open new markets. Companies must also navigate complex regulatory environments, ensuring compliance and timely approvals for newer formulations.

Healthcare providers and payers should emphasize evidence-based prescribing, balancing clinical efficacy with cost considerations. Patient education programs aimed at improving adherence can also bolster market stability.

---

Key Takeaways

• The venlafaxine hydrochloride market has transitioned from growth to maturity, driven by patent expirations and generics proliferation.
• Despite declining revenues, the growing global mental health burden sustains steady demand, especially in emerging markets.
• Competition from newer agents and side effect considerations challenge venlafaxine's market share.
• Innovation through formulation developments and expanding indications could mitigate revenue declines.
• Regulatory, reimbursement, and demographic factors significantly influence the drug’s financial trajectory.

---

Conclusion

Venlafaxine hydrochloride’s market trajectory exemplifies the lifecycle challenges faced by branded pharmaceuticals amid patent expiries and rising generic competition. While near-term growth prospects remain limited, strategic innovation, geographic expansion, and tailored treatment approaches could sustain its relevance. Stakeholders must adapt to evolving regulatory and market conditions to maximize value from this established antidepressant.

---

FAQs

Q1: How have patent expiries affected venlafaxine’s market revenue?
Patent expirations led to a surge in generic availability, resulting in a significant decline in branded formulary sales and overall revenues.

Q2: What are the primary factors influencing venlafaxine’s future market growth?
Demographic trends, clinical guideline changes, emerging competition, and innovation in formulations and indications are key factors.

Q3: Can new formulations of venlafaxine extend its market viability?
Yes, extended-release variants or combination products can open niche markets and improve patient compliance, potentially stabilizing or boosting revenues.

Q4: How do regulatory policies impact venlafaxine’s market trajectory?
Regulatory approvals, safety mandates, and reimbursement frameworks directly influence product availability, pricing, and market penetration.

Q5: What role do emerging markets play in the future of venlafaxine?
Growing healthcare infrastructure and increasing mental health awareness position emerging markets as significant growth avenues for venlafaxine.

---

Sources

1. MarketWatch. “Antidepressants Market Size, Growth & Trends Analysis.” 2022.
2. NICE Guideline on Depression. National Institute for Health and Care Excellence, 2019.
3. IMS Health Data. “Global Sales Data for Antidepressants,” 2018.